Palo Alto– Atropos Health is deepening its investment in oncology with new personnel appointments and product enhancements designed to expand its real-world evidence (RWE) offerings for drug development, clinical research, and treatment innovation. The company announced a series of strategic moves aimed at boosting its presence in the rapidly growing field of oncology data and analytics.
As part of this initiative, Atropos Health has bolstered its Atropos Evidence™ Network by integrating oncology-focused real-world data (RWD) from Ontada, expanding its Oncology MultiModal Network. The move reflects the increasing demand for tailored RWE in oncology, where researchers and clinicians rely on real-time insights to guide both treatment decisions and pharmaceutical development.
To support this expanded scope, Atropos Health has brought on several experienced professionals with deep roots in healthcare technology and oncology. Cory D. Wiegert has been named Chief Operating Officer, bringing over 25 years of experience in enterprise software and healthcare IT. His previous roles include leading the launch of AI-powered decision platforms and overseeing value-based care datasets at Integra Connect. He has also held leadership positions at CancerLinQ, IBM Watson Health, and Siebel Systems.
Dr. Morgan Cheatham has joined the Board of Directors as a Board Observer. He currently serves as Partner and Head of Healthcare and Life Sciences at Breyer Capital and has a background in early-stage healthcare investments, including companies like Abridge and Hinge Health. Dr. Cheatham is also pursuing a clinical genetics fellowship at Harvard/Boston Children’s and plays an active role on the editorial team for NEJM AI and the Board of the Coalition for Health AI.
Leading the data science efforts at Atropos is Jason Jones, who previously served as Chief Data Scientist at Health Catalyst and held senior research roles at Kaiser Permanente. His background includes work in medical informatics at Intermountain Healthcare and leadership experience at Bayer HealthCare and UnitedHealth Group.
“We’re investing heavily in both product and personnel when it comes to applying RWE to oncology practice and research and development,” said Dr. Brigham Hyde, CEO and co-founder of Atropos Health. “Bringing on additional oncology-specific expertise signals our further commitment to advancing life-saving treatments in oncology.”
In addition to the Ontada partnership, Atropos Health announced that Norstella, already a strategic partner, will now contribute oncology data to the Atropos Evidence Network. This expansion further strengthens what the company describes as the market’s leading federated evidence network for oncology research.
